Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Supply issues

Accord's phenytoin sodium 100mg capsules out of stock until early May 2020

The pharmaceutical manufacturer Accord has said that its phenytoin sodium NRIM 100mg capsules, used for the management of epilepsy, will be out of stock until early May 2020.

In a supply alert issued to pharmacists on 10 January 2020 by the Department of Health and Social Care (DHSC), Accord said that the disruption was due to ”a regulatory change at their manufacturing site”.

The drug is used for the control of tonic-clonic seizures, partial seizures or a combination of the two.

Phenytoin is a category 1 anti-epileptic, meaning patients should not usually be switched between different manufacturers of the drug.

However, the DHSC said in the alert that patients who require switching as a result of the supply disruption should be prescribed Flynn Pharma Ltd’s phenytoin sodium 100mg capsules.

The alert also advised healthcare professionals to monitor patients closely during the switching period.

Patients who cannot be switched to Flynn Pharma Ltd’s version may be considered for an alternative licensed phenytoin formulation, the DHSC said, but advised that care shoud be taken where dosage forms are changed.

Disruption to the supply of phenytoin sodium 100mg capsules comes after the DHSC announced a supply issue affecting all strengths of Convulex (valproic acid) capsules on 23 December 2019, resulting from a pack size update, which is expected to continue until April 2020.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207567

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.